Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Bruke teknologi for å forbedre funksjonen for eldre latinoer med funksjonshemminger i undertjente områder

4. november 2026 oppdatert av: University of Puerto Rico

Teknisk aktivert funksjonell helse: bygge bro mellom primæromsorgshull for eldre latinoer med funksjonshemming i undertjente lokalsamfunn

This project aims to test a culturally appropriate assistive technology (AT) intervention called VIVE-AT to help older Latinos with disabilities improve their function and quality of life. The researchers will first refine the VIVE-AT program based on feedback from a Community Advisory Board and focus groups with older Latinos with disabilities. Then, 76 older Latinos with disabilities will be recruited from a primary care clinic serving low-income communities in Puerto Rico. They will be randomly assigned to either receive the VIVE-AT intervention in the primary care clinic or be placed on a waitlist with regular phone calls. All participants will continue to receive standard care at the clinic.

Studieoversikt

Status

Rekruttering

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

Functional disabilities (FDs), defined as difficulties in performing daily activities, constitute a significant public health problem associated with increased dependency, poor health outcomes, diminished quality of life, institutionalization, and premature death. Older Latinos residing in Puerto Rico (PR) are disproportionately affected by FDs, with one of the highest rates of FDs (58%) in the US and its territories. Research has demonstrated positive outcomes from employing assistive technology (AT) devices, such as jar openers, sock aids, and canes, among older adults with FDs, thereby enhancing their functioning, participation, and capacity to remain at home or in the community for a longer period. However, Latinos are among the least likely to utilize AT. Given the dearth of culturally competent assistive technology interventions for Latinos, along with the scarcity of rehabilitation professionals and assistive technology services in primary healthcare facilities, this project leverages preliminary data from a prior study that assessed the feasibility of the Viviendo las Ventajas de la Asistencia Tecnológica; (VIVE-AT for short; Living the Advantages of Assistive Technologies) intervention. The specific aims of this project are to:

  1. refine the protocol of the VIVE-AT to align with the unique needs of the primary health care clinic;
  2. assess the efficacy of the VIVE-AT in comparison to a waitlist control arm, in decreasing FDs and improving the quality of life among Latinos aged ≥65 years post-intervention and at six months;
  3. evaluate whether proposed mechanisms of change in FDs, specifically knowledge of AT, motivation for using AT, self-efficacy for using AT, and use of AT, account for the reduction in FDs post-intervention.

To achieve these aims, the interdisciplinary team of this project will first refine the intervention based on recommendations from participants in the feasibility study, as well as input from the Community Advisory Board and older Latinos with FDs through iterative focus groups (Aim 1). Subsequently, 76 older Latinos with physical FDs recruited from a primary health care facility serving low-income communities in PR will be randomly assigned to either the VIVE-AT intervention group (n=38) or a waitlist + attention calls controlled condition group (n=38) to assess its efficacy and mechanisms of change (Aims 2 and; 3). All participants will receive standard usual care at the primary health care center. Participants in the intervention group will attend a weekly, two-hour group session for 6 weeks, facilitated by trained healthcare workers, focusing on self-management of FDs through AT. Additionally, participants will receive up to five AT devices tailored to their specific functional disabilities needs, along with training on their usage. All participants will be assessed at baseline, post-intervention, and six months after intervention. The goals of the VIVE-AT are to encourage participants to use AT devices to self-manage their FDs and improve their quality of life. This approach will contribute to scientific knowledge and inform a subsequent scalable multisite Hybrid Type I Randomized Controlled Trial designed to evaluate its effectiveness in reducing physical function disabilities among older Latinos in primary healthcare settings in the U.S. and P.R.

Studietype

Intervensjonell

Registrering (Antatt)

76

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

      • San Juan, Puerto Rico, 00936-5067
        • Rekruttering
        • University of Puerto Rico Medical Sciences Campus
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Elsa M Orellano-Colón, Ph.D.
      • San Juan, Puerto Rico
        • Rekruttering
        • HealthproMed Foundation, Inc.
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

65 år og eldre (Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Spanish speaking Latino adults ≥65 years
  • With a physical function impairment (PROMIS-HAQ T-Score ≤45)
  • Living independently in the community (not requiring supervision to perform their daily living activities)
  • Self-reported ability to participate in a 6 weeks of group intervention
  • Having no plans to move for the next 12 months

Exclusion Criteria:

  • Currently residing in a nursing or group home
  • Receiving home healthcare services
  • Having a significant cognitive impairment as evidenced by a score ≤23 in the Mini Mental State Examination (MMSE)

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Enkelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: (VIVE-AT) - Translation: Living the Advantages of Technological Assistance

The VIVE-AT program consists of a six-week, once-a-week, 2-hour group educational intervention guided by the social cognitive model. It is facilitated by primary care and community health workers in a primary healthcare clinic. The intervention aims to teach older Latinos self-management strategies to increase the adoption and use of assistive technology devices that enhance their function in daily activities. VIVE-AT is designed to support behavioral change by providing up to five assistive technology devices to participants, along with information, instruction, demonstration, action planning, and guided practice in using the devices.

It comprises 2-hour small group sessions of 8-10 participants, once a week, for six weeks of participatory discussions, experiential learning, multimodal instructions, and demonstration and practice with selected assistive technology devices (ATDs). The content of the VIVE-AT weekly sessions is as follows: Week 1 - Introduction to ATDs, funding, and resources; Week 2 - ATDs for self-care and toilet use; Week 3 - ATDs for mobility; Week 4 - ATDs for dressing; Week 6 - ATDs for cooking and home tasks. Each session is designed with the following components: monitoring of participants' weekly goals; providing information on ATDs, resources, and services; reflection on the advantages and disadvantages of using these ATDs; hands-on practice with selected ATDs; goal setting and addressing barriers to using ATDs. Group sessions will incorporate visual aids, including modeling and videos of older individuals using ATDs accessed through an AT web app in a tablet provided by this project.

Aktiv komparator: Waitlist Control

Participants in the waitlist control group will receive weekly attention calls providing general health advice during the 6-week intervention period. They will also receive usual care for the initial 6 months post-randomization, followed by crossover to the VIVE-AT intervention.

Ten minutes of attention calls, once a week for six weeks, to the waitlist control participants will offer general health advice on topics like nutrition, exercise, sleep, stress, and social connections. These calls emphasize participant well-being without touching upon the specific VIVE-AT content, maintaining a clear distinction from the intervention group.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Physical Function as Assessed by the PROMIS Short Form v2.0 - Physical Function 24a (PROMIS-HAQ)
Tidsramme: Baseline, at the end of the intervention (6 weeks), and at 6 months post-intervention

This is a patient-reported outcome measure designed to assess physical FDs in adults across the categories of dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, errands, and chores. It comprises 20 items on a 5-point Likert-type scale, ranging from 5 "without difficulty" to 1 "unable to do".

Baseline, at the end of the intervention (6 weeks), and at 6 months post-intervention
Quality of Life as Assessed by PROMIS Scale v1.2 - Global Health
Tidsramme: Baseline, at the end of the intervention (6 weeks), and at 6 months post-intervention

This is a 10-item health-related quality of life measure with five domains: physical health, pain, fatigue, mental health, and social health, along with an overall health assessment. It also includes two subscales: Global Mental Health (GMH) and Global Physical Health (GPH).

Baseline, at the end of the intervention (6 weeks), and at 6 months post-intervention

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Use of Assistive Technology Devices as Assessed by Assistive Technology Awareness Scale (ATUAS)
Tidsramme: Baseline, at the end of the intervention (6 weeks), and at 6 months post-intervention

The ATUAS assesses participants' knowledge of 44 assistive technology devices. Participants are presented with photographs and names of the devices and asked if they possess each item. If the answer is 'No,' further questions will determine whether they use it (code 2) or not (code 1), are aware of its existence (code 3), or neither (code 4). Responses will be recoded into two categories: used (code 2) and not used (codes 1, 3, and 4) to calculate assistive technology device usage.

Baseline, at the end of the intervention (6 weeks), and at 6 months post-intervention
Assistive Technology Knowledge as Assessed by Assistive Technology Use and Awareness Scale (ATUAS)
Tidsramme: Baseline, at the end of the intervention (6 weeks), and at 6 months post-intervention

The ATUAS assesses participants' knowledge of 44 assistive technology devices. Participants are presented with photographs and names of the devices and asked if they possess each item. If the answer is 'No,' further questions will determine whether they use it (code 2) or not (code 1), are aware of its existence (code 3), or neither (code 4). Assistive technology knowledge is assessed by re-coding the answer for each assistive technology into two categories: aware (codes 1, 2, 3) versus not aware (code 4).

Baseline, at the end of the intervention (6 weeks), and at 6 months post-intervention
Motivation to Use Assistive Technology as Assessed by Attitudes Towards Assistive Device Scale (AADS)
Tidsramme: Baseline, at the end of the intervention (6 weeks), and at 6 months post-intervention

The AADS consists of 12 items designed to measure older adults' attitudes (motivation), including the substitution of care, the financial aspect of care, and the effect on privacy. It utilizes a Likert scale with 5 points, ranging from 5 (totally agree) to 1 (totally disagree), with interval scores ranging from 12 to 60. A high score indicates a positive attitude.

Baseline, at the end of the intervention (6 weeks), and at 6 months post-intervention
Intention to Use Assistive Technology as Assessed by Intention to Use Assistive Device Scale
Tidsramme: Baseline, at the end of the intervention (6 weeks), and at 6 months post-intervention

This measure consists of three items presenting increasing levels of intention (motivation) to use assistive technology devices. It employs a 5-point Likert scale, ranging from 1 (I do not have the intention to do this at all) to 5 (I certainly have the intention to do this). The total score ranges from 3 to 15; higher scores indicate a strong intention to use assistive technology devices.

Baseline, at the end of the intervention (6 weeks), and at 6 months post-intervention
Self-efficacy as Assessed by Self-efficacy Regarding Assistive Device Use
Tidsramme: Baseline, at the end of the intervention (6 weeks), and at 6 months post-intervention

This measure assesses self-efficacy for using assistive technology devices with three items, each representing increasing barriers. The interval scale ranges from 3 to 15; a higher score indicates higher self-efficacy.

Baseline, at the end of the intervention (6 weeks), and at 6 months post-intervention

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Participation rates
Tidsramme: At the end of the intervention (6 weeks)

The percent of eligible older Latinos who were enrolled (goal: ≥ 80%)

At the end of the intervention (6 weeks)
Retention rates
Tidsramme: At the end of the intervention (6weeks) and at 6 months post-intervention

The percent of older Latinos who complete the study measures at the end of the intervention and at 6 months post-intervention (goal: ≥ 80%).

At the end of the intervention (6weeks) and at 6 months post-intervention
Attrition rates
Tidsramme: At the end of the intervention (6 weeks) and 6 months post-intervention

The percent of participants who drop out or are lost to follow-up at the end of the intervention and at 6 months post-intervention, with reasons recorded when known (goal: ≤ 20%).

At the end of the intervention (6 weeks) and 6 months post-intervention
Completion rates
Tidsramme: At 6 months post-intervention

The percent of participants completing at least 4 of 6 group sessions (goal: ≥ 80%).

At 6 months post-intervention
Acceptability as Assessed by Acceptability: Assessment will be conducted using the Intervention Acceptability and Implementation Questionnaire
Tidsramme: At the end of the intervention (6 weeks)

This questionnaire is based on the key dimensions outlined in the Theoretical Framework of Acceptability, which include affect, burden, perceived effectiveness, ethicality, coherence, opportunity costs, and self-efficacy. It features open-ended questions to further explore suggested improvements, identify successful components, and understand contextual issues that influenced the implementation of the intervention in primary care clinic, all based on the Practical Robust Implementation and Sustainability Model (PRISM). The goal is to achieve a mean satisfaction level of ≥ 80%.

At the end of the intervention (6 weeks)
Cost
Tidsramme: Baseline, during the intervention, at the end of the intervention (6 weeks), and at 6 months post-intervention

The researchers will document total intervention costs, costs per participant, and marginal costs related to changes in FDs PROMIS-HAQ T-scores, valuing resources at competitive market rates. Costs will be estimated in constant dollars using the Prospective Payment System Index. Key resource categories include participant recruitment, intervention preparation, labor costs, training, supervision, and materials. The researchers will distinguish between research-based and intervention costs. Emergency room visits, their costs, reasons, and institutional costs (hospitalizations) will be tracked. Primary care physician visits will be documented over 32 weeks (including a 6-week intervention and 6-month follow-up). Additionally, the researchers will analyze mortality incidence during the intervention and the subsequent 32 weeks. Data will be sourced from the primary care clinic for all participants, with detailed documentation of activities and resources used throughout the study.

Baseline, during the intervention, at the end of the intervention (6 weeks), and at 6 months post-intervention

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

1. august 2026

Primær fullføring (Antatt)

31. desember 2027

Studiet fullført (Antatt)

31. desember 2027

Datoer for studieregistrering

Først innsendt

17. mai 2024

Først innsendt som oppfylte QC-kriteriene

17. mai 2024

Først lagt ut (Faktiske)

22. mai 2024

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

9. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

4. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • 2405230330

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

De-identified quantitative data that can be publicly shared will be formatted for widely available statistical packages such as R, Statistical Package for the Social Sciences (SPSS), STATA, and Statistical Analysis System (SAS). All shared study materials, data, and metadata will be made publicly available through the University of Puerto Rico Institutional Repository at the University of Puerto Rico Institutional Digital Repository website at https://repositorio.upr.edu/. Data will be assigned a Digital Object Identifier (DOI) and searchable via the University of Puerto Rico Institutional Repository and other search engines.

IPD-delingstidsramme

Data and metadata will be deposited into the repository at the time of publication or by the end of the project period, whichever comes first. Data will be preserved for three years following the end of the grant period.

Tilgangskriterier for IPD-deling

The study's Individual Participant Data (IPD) would be accessible to the academic community and the public. This repository serves as a digital storage site for the scientific and creative work of the University of Puerto Rico. They will be able to access all shared study materials, data, and metadata. To access the repository, users can visit the University of Puerto Rico Digital Institutional Repository website at https://repositorio.upr.edu. The repository allows for the searching and browsing of content, which includes faculty research works.

IPD-deling Støtteinformasjonstype

  • STUDY_PROTOCOL
  • SEVJE

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .